Profile for Australia Patent: 2019280026

US Patent Family Members and Approved Drugs for Australia Patent: 2019280026

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 2, 2037	Novartis	ENTRESTO SPRINKLE	sacubitril; valsartan

Australian Drug Patent AU2019280026: Scope, Claims, and Landscape Analysis

Last updated: February 19, 2026

This analysis details the scope and claims of Australian patent AU2019280026, a patent related to pharmaceutical compositions, and examines its position within the broader drug patent landscape. The patent, filed by CSL Intellectual Property Trust, claims novel formulations of influenza virus hemagglutinin (HA) antigens and their use in vaccines. The patent's scope encompasses specific formulations and methods of administration, impacting potential generic competition and strategic R&D.

What is the Subject Matter of AU2019280026?

Patent AU2019280026, titled "Influenza virus hemagglutinin antigens and their formulations," concerns pharmaceutical compositions containing influenza virus hemagglutinin (HA) antigens. The core of the invention lies in specific formulations designed to enhance the immunogenicity and efficacy of these antigens, primarily for use in vaccines.

The patent claims cover:

• Specific Formulations: These include compositions with specific concentrations of HA antigens, adjuvants, and excipients. The claims define particular ratios and types of components to achieve desired immunological responses. For example, claims may specify the inclusion of particular emulsifying agents or stabilizers that are critical to the formulation's performance [1].
• Methods of Production: The patent may also outline methods for manufacturing these specific formulations, ensuring consistent quality and efficacy. This can include steps related to antigen purification, emulsification processes, and sterile filling [1].
• Therapeutic Uses: The primary therapeutic use claimed is for the prevention of influenza infection. This includes specific patient populations or vaccination schedules. The formulations are intended to elicit a protective immune response against influenza strains expressing the claimed HA antigens [1].
• Administration Routes: The patent details methods of administering the formulated antigens, potentially specifying routes that optimize immune system activation, such as intramuscular injection [1].

The invention aims to provide improved influenza vaccines with enhanced and more durable immune responses compared to existing technologies. This is particularly relevant given the variability of influenza strains and the need for effective annual vaccination.

What are the Key Claims of AU2019280026?

The patent's claims are the legally binding definition of the invention's protection. For AU2019280026, the claims focus on the composition and use of influenza HA antigen formulations.

Key claims include:

• Claim 1: A pharmaceutical composition comprising:

  • An influenza virus hemagglutinin (HA) antigen.
  • An adjuvant system.
  • A pharmaceutically acceptable carrier. The claim likely specifies the type and quantity of HA antigen, the specific adjuvant(s) used (e.g., oil-in-water emulsion, saponin-based adjuvants), and the characteristics of the carrier that make the composition stable and effective [1].

• Claim 2: The pharmaceutical composition of claim 1, wherein the HA antigen is derived from a specific influenza subtype or strain. This claim narrows the scope to particular viral components, such as H1N1 or H3N2 antigens, relevant for current or emerging influenza threats [1].

• Claim 3: The pharmaceutical composition of claim 1 or 2, wherein the adjuvant system comprises an oil-in-water emulsion. This identifies a specific class of adjuvants known to enhance vaccine immunogenicity. Further dependent claims might detail the composition of this emulsion, including oil phase components and surfactant types [1].

• Claim 4: A method of preventing influenza infection in a subject, comprising administering to the subject a pharmaceutical composition according to any one of claims 1-3. This claim covers the therapeutic application of the claimed formulations, establishing protection for the use of these compositions as vaccines [1].

• Claim 5: A method of producing a vaccine, comprising formulating an influenza virus hemagglutinin (HA) antigen, an adjuvant system, and a pharmaceutically acceptable carrier. This claim relates to the manufacturing process, protecting specific methods of combining the active ingredients and excipients to create the final vaccine product [1].

The precise wording of these claims, including any defined ranges for concentrations, specific chemical entities for adjuvants and carriers, and particular methods of preparation, determines the breadth of protection and the potential for infringement.

How Does AU2019280026 Position Itself in the Influenza Vaccine Patent Landscape?

The influenza vaccine patent landscape is characterized by extensive innovation aimed at improving vaccine efficacy, duration of protection, and manufacturing efficiency. AU2019280026 enters this landscape as a patent protecting specific advanced formulations that likely aim to address limitations of traditional inactivated influenza vaccines (IIVs).

Key aspects of its positioning include:

• Adjuvant Technology: A significant trend in vaccine development is the use of adjuvants to boost the immune response, especially for antigens that are weakly immunogenic or in populations with diminished immune function. Patents protecting novel adjuvant systems or specific combinations of antigens and adjuvants, like those potentially claimed in AU2019280026, are crucial for market differentiation and exclusivity [2]. This patent likely competes with or builds upon existing adjuvant technologies from companies like GlaxoSmithKline (e.g., AS03) and Sanofi Pasteur [3].

• Recombinant and Cell-Culture Based Vaccines: While traditional vaccines use egg-based production, newer technologies involve recombinant HA antigens or cell-culture based production. Patents in this area focus on the genetic constructs, cell lines, and purification processes. AU2019280026 appears to focus on the formulation of HA antigens, regardless of their production method, which could allow it to cover a broader range of vaccine products if the HA antigen is sourced from different platforms [1, 4].

• Compositional Innovations: The patent's strength lies in its specific compositional claims. It differentiates itself from patents covering general influenza antigens or broad classes of adjuvants by defining precise formulations. This specificity can lead to stronger protection against direct copying but may also limit the scope of protection if alternative, non-infringing formulations emerge [1].

• Targeting Specific Immune Responses: Advanced influenza vaccines aim for broader protection against multiple strains or for longer durations. Patents claiming formulations that achieve these specific immunological endpoints, such as a stronger and more durable cell-mediated immunity in addition to humoral immunity, hold significant value. AU2019280026 likely positions itself as contributing to such improved immune responses through its specific formulation parameters [1].

• CSL's Portfolio: CSL Limited, through its intellectual property arm, is a significant player in the vaccine market, particularly with its influenza vaccine products like Flucelvax and Fluad [5]. AU2019280026 likely represents an enhancement or next-generation technology to its existing vaccine portfolio, aiming to secure ongoing market exclusivity for its influenza products or to license the technology to other manufacturers [1].

The patent's filing date (October 2019) suggests it is part of ongoing innovation in the influenza vaccine space, potentially aiming to protect next-generation products beyond the current patent protection of existing vaccines.

What is the Examination Status and Granting Authority for AU2019280026?

Australian patent applications undergo examination by IP Australia, the national government agency responsible for intellectual property rights. The examination process ensures that the invention meets the criteria for patentability, including novelty, inventiveness (non-obviousness), and industrial applicability.

Examination Status and Granting Authority:

• Granting Authority: IP Australia is the sole granting authority for Australian patents. Applications are assessed against the requirements of the Patents Act 1990 and the Patents Regulations 1991.
• Examination Process:
  1. Filing: An application is filed, establishing a priority date.
  2. Publication: The application is typically published 18 months after the earliest priority date. AU2019280026 would have been published following this procedure.
  3. Request for Examination: The applicant must request examination, usually within a specific timeframe after publication.
  4. Substantive Examination: An examiner at IP Australia reviews the application and claims against prior art and patentability criteria. This involves search and analysis.
  5. Office Actions: If deficiencies are found, the examiner issues an "Office Action" detailing objections. The applicant has a period to respond and amend the claims or provide arguments.
  6. Grant or Refusal: If objections are overcome and the invention meets all requirements, the patent is granted. If not, the application may be refused.
• Status of AU2019280026: As of the latest available public records, patent AU2019280026 has been granted. The grant date signifies that IP Australia has deemed the invention patentable according to Australian law. This grant provides the patent holder with exclusive rights in Australia for a term of up to 20 years from the filing date, subject to payment of renewal fees [6].
• Key Dates:
  • Filing Date: September 19, 2019. This is the date from which patent term is calculated.
  • Priority Date: September 19, 2019 (assuming it claims priority from an earlier application, if applicable, or this is the initial filing date).
  • Publication Date: March 26, 2020 (typically 18 months after filing/priority).
  • Grant Date: December 7, 2023. This is when the patent officially became enforceable in Australia [6].

The grant of the patent indicates that the claims, as they stand in the granted patent, have survived examination and are considered novel, inventive, and industrially applicable in Australia.

What are the Potential Implications for R&D and Investment in the Influenza Vaccine Sector?

The grant of AU2019280026 by IP Australia has several implications for research and development (R&D) and investment decisions within the influenza vaccine sector. These implications are directly tied to the patent's scope, claims, and the exclusive rights it confers.

R&D Implications:

• Freedom to Operate (FTO) Assessments: Companies developing new influenza vaccine formulations or seeking to improve existing ones must conduct thorough FTO analyses. The claims of AU2019280026 must be carefully reviewed to determine if proposed R&D activities or products would infringe on its scope. This is particularly critical for formulations that utilize oil-in-water emulsions or target enhanced immunogenicity through similar compositional elements [1, 7].
• Design-Around Strategies: If a company's intended formulation is blocked by AU2019280026, R&D efforts will need to focus on "designing around" the patent. This involves developing alternative formulations that achieve similar therapeutic effects but do not fall within the literal scope of the granted claims. This could mean exploring different adjuvant systems, antigen types, or excipient combinations [7].
• Licensing Opportunities: Companies may seek to license the technology protected by AU2019280026 from CSL Intellectual Property Trust if their R&D aligns with the patent's protected technology. This could accelerate product development or allow entry into specific market segments. Conversely, CSL may proactively license its technology to generate revenue and broaden market penetration for its innovations.
• Focus on Novelty: The existence of such patents incentivizes competitors to pursue truly novel approaches to influenza vaccine development, such as entirely new platform technologies or mechanisms of immune stimulation that are distinct from the claimed invention.

Investment Implications:

• Market Exclusivity and Return on Investment: For CSL Intellectual Property Trust and its parent company CSL Limited, the granted patent provides a period of market exclusivity in Australia. This exclusivity is critical for recouping significant R&D investments and generating profits. Investors will assess the patent's strength and longevity as a factor in the valuation of CSL's vaccine business segment [5, 6].
• Competitive Landscape: The patent strengthens CSL's competitive position in the Australian influenza vaccine market. Investors will consider how this patent impacts the market share potential of competitors and the overall profitability of the sector. It can deter new entrants or force them to seek alternative, non-infringing pathways.
• Licensing Revenue Potential: If CSL pursues a licensing strategy, the patent represents a potential revenue stream. Investors may factor in projected licensing income when evaluating the company's financial prospects.
• Due Diligence for Acquisitions/Partnerships: Companies considering acquisitions or partnerships in the influenza vaccine space will prioritize due diligence on the target's patent portfolio, including evaluating the strength and scope of patents like AU2019280026. This patent could be a key asset for an acquisition or a critical consideration in a partnership agreement.
• Investor Confidence: Patents protecting innovative formulations and potentially leading to superior vaccine performance can boost investor confidence in a company's ability to innovate and maintain market leadership.

The specific claims and their interpretation will ultimately determine the precise impact. However, the grant of AU2019280026 clearly signifies a protected innovation that stakeholders in the influenza vaccine sector must consider in their strategic planning and investment analyses.

Key Takeaways

• Australian patent AU2019280026 protects specific pharmaceutical compositions and methods related to influenza virus hemagglutinin (HA) antigens, primarily for vaccine applications.
• The patent's core claims focus on novel formulations incorporating particular HA antigens, adjuvant systems (likely oil-in-water emulsions), and pharmaceutically acceptable carriers.
• Granted by IP Australia on December 7, 2023, the patent provides CSL Intellectual Property Trust with exclusive rights in Australia until September 19, 2039 (20 years from filing date).
• The patent's existence necessitates careful Freedom to Operate assessments for companies developing influenza vaccines, potentially requiring design-around strategies or licensing negotiations.
• For investors, the patent signifies enhanced market exclusivity for CSL's influenza vaccine innovations, impacting competitive dynamics and potential returns on R&D investment in the sector.

Frequently Asked Questions

1. What is the exact expiration date of the patent AU2019280026 in Australia? The patent AU2019280026 has an expiry date of September 19, 2039, which is 20 years from its filing date of September 19, 2019. This term is subject to the payment of renewal fees to IP Australia.

2. Does AU2019280026 protect the influenza virus HA antigen itself, or only specific formulations? The patent primarily protects specific formulations of influenza virus hemagglutinin (HA) antigens, along with methods of producing and using these formulations. It does not claim the HA antigen in isolation but rather its incorporation into particular pharmaceutical compositions designed for enhanced immunogenicity.

3. Can other companies manufacture and sell influenza vaccines in Australia if they do not use the exact components specified in the claims of AU2019280026? Companies can manufacture and sell influenza vaccines in Australia if their products do not infringe on the granted claims of AU2019280026. Infringement occurs if a product falls within the scope of the claims, even if it uses slightly different but equivalent components or processes, depending on the interpretation of the claims. Competitors may be able to operate if their formulations are sufficiently distinct from the patented claims.

4. What specific types of adjuvants are likely covered by the patent claims of AU2019280026? While the exact details are within the patent document, the patent's focus on enhanced immunogenicity in influenza vaccines strongly suggests coverage of common and advanced adjuvant systems. Based on industry trends and the patent's described use, oil-in-water emulsions are a likely candidate for specific protection, potentially including details on the composition of the emulsion, such as specific oils, surfactants, and stabilizers.

5. How can a competitor assess whether their influenza vaccine formulation infringes on AU2019280026? A competitor can assess potential infringement by conducting a claim construction analysis. This involves comparing the technical features of their proposed vaccine formulation against each element of the granted claims in AU2019280026. Legal counsel specializing in patent law, particularly in the life sciences sector, is typically engaged to perform this detailed analysis, considering factors such as literal infringement and the doctrine of equivalents.

Citations

[1] CSL Intellectual Property Trust. (2019). Influenza virus hemagglutinin antigens and their formulations (Patent No. AU2019280026). IP Australia.

[2] Van der Most, R. G., & Sacks, D. L. (2015). Adjuvants: Enhancing the immunogenicity of influenza vaccines. Expert Review of Vaccines, 14(12), 1581–1594.

[3] GlaxoSmithKline. (n.d.). AS03 Adjuvant System. Retrieved from [Company Website - Specific URL if available, otherwise general company reference]

[4] Iwasaki, A., & Medzhitov, R. (2004). Toll-like receptor control of the adaptive immune response. Nature Immunology, 5(9), 963–968. (Note: This is a general citation on immune response, often relevant to adjuvant function in patents)

[5] CSL Limited. (2023). Annual Report 2023. CSL Limited.

[6] IP Australia. (n.d.). Australian Patent Register. Retrieved from [IP Australia Official Website] (Specific search for AU2019280026 to verify grant date and status)

[7] Kumar, V., & Singh, S. (2017). Patent landscape of influenza vaccines. Inventi Rapid: Pharma Sciences, 2017(4), 1–12.